Rx Medicare

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company’s LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine…

Read More…

Related Posts

• QRxPharma Initiates Second Pivotal Phase 3 Study Of MoxDuo(TM)IR Dual-Opioid(TM) For NDA Submission
• King Pharmaceuticals Announces Positive Results From A 12-Month Open-Label Safety And Efficacy Study Of EMBEDA? Extended Release Capsules
• Baxter Presents Clinical Efficacy Results From Phase III Study Of Seasonal Flu Vaccine
• Vaccinating Kids Against Flu Protects Whole Community, Canadian Study
• WHO Will Meet To Decide If H1N1 Has Peaked
• SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN’s Ability To Enhance Response To H1N1 Vaccine
• Protecting Patients: Study Shows That Johns Hopkins Flu Vaccination Rates Are Twice The National Average
• Study Investigates Who Is Most Likely To Take Precautions During A Pandemic
• Face Masks And Hand Hygiene Can Help Limit Influenza’s Spread According To Study
• Drive-Through Emergency Service Effective Response To Pandemic, Stanford Study Shows
• SciClone And Sigma-Tau Announce Positive Preliminary Results In Clinical Study Examining ZADAXIN’S Ability To Enhance Response To H1N1 Vaccine
• Flu Pandemics May Be Worsened By Short-Term School Closures, Pitt Study Finds
• ImmuneRegen BioSciences(R) Reports Additional Positive Results From Study Of Homspera(R) In Treating Highly Pathogenic Influenza
• Poll: Forty Percent Of Americans Will Change Holiday Plans Due To H1N1 Virus
• H1N1 Swine Flu Deaths Reveal New Pattern Of The Disease, Brazilian Study

Tags: efficacy, levadextm, pharmaceuticals, pivotal, require, second, study, submission, will

This entry was posted on Saturday, January 16th, 2010 at 5:01 am and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.